Table 3.
In vitro experiments with SSAs and their results.
Somatostatin analog | Cell line | Mechanism | Result | References |
---|---|---|---|---|
SSA RC-160+CCK | Chinese Hamster Ovary (CHO) cells | Inhibition of CCK-induced intracellular cGMP formation and activation of p42-MAP kinase phosphorylation and activity | Inhibition of cell proliferation in response to the administration of cholecystokinin | [93] |
Lanreotide | Human HepG2 cells | Potential action through the SST3 and/or insulin and IGF | Antiproliferative effect proportional to the SSA dose established | [78] |
Octreotide | Human BEL-7402 cells | Potentially correlated to the antineoplastic effect of SSA | Antiproliferative effect proportional to the SSA dose established | [80] |
Octreotide | SMMC-7721 HCC cells | Antineoplastic action potentially attributable to decreased DNA synthesis | Antiproliferative and apoptotic effect and also decreased tumor growth in xenografted mice | [79] |
SSA RC-160 | Chinese Hamster Ovary (CHO) DG-44 cells | A Gi/o protein-coupled receptor inhibits cell proliferation via ERK signaling | Inhibition of cell proliferation | [87] |
Octreotide | Human HepG2, SMMC-7721, and L-02 cells | Some mechanism most probably associated with SST3 | Antiproliferative effect proportional to the SSA dose established | [44] |
Receptor agonists | Human HepG2, HuH7, and hepatic stellate cells (HSCs) | Signaling pathways linked to SSTs | Reduced migration of cancer cells but no antiproliferative effect observed | [52] |
Octreotide±lamivudine | Human HepG2 and HepG2x | Signaling pathways linked to SSTR2 and SSTR5 | Increased apoptotic effect on the HepG2 cell line | [82] |
L-779,976 | HEK 293 cell clone | Inhibiting adenylate cyclase, activating ERK1/2, and inducing the cyclin-dependent kinase inhibitor p27(Kip1) | Inducement of cell cycle arrest | [88] |
Octreotide | SMMC-7221 cells | Activation of the Fas-FasL ligand system | Inducement of apoptosis | [47] |
Octreotide | Human Bel-7402 | Some mechanisms linked to SSTR2 | No antiproliferative effect but no xenografted HCC development | [83] |
Octreotide | Human HepG2 cells | Caspase-mediated signaling pathways | Inhibition of proliferation at high octreotide doses and proliferation of promotion at low octreotide doses | [96] |
Octreotide | Rat hepatic stellate cells (HSCs) | A mechanism related to the cytokine environment of HSCs | Varied effect. General reduction in collagen synthesis related to PDFG and TGFb1 | [85] |
Octreotide, lanreotide, SOM230 | Human Bel-7402 cells | Some mechanisms linked to SSTR expression variation | Apoptotic effect observed and improved survivability and life quality after the xenograft on mice | [84] |